Change in circulating tumor DNA (ctDNA) one month after treatment initiation predicts progression-free and overall survival in patients with dMMR/MSI-H metastatic colorectal cancer receiving immune checkpoint inhibitors, offering a potential biomarker for therapeutic decision-making.